Tissue Engineering and Biomicrofluidics Laboratory, School of Biomedical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi, India.
Department of Biomedical Engineering, University of Engineering (UCE), Osmania University, Hyderabad, India.
J Biomater Sci Polym Ed. 2024 Aug;35(12):1922-1946. doi: 10.1080/09205063.2024.2363080. Epub 2024 Jul 5.
Recent advancements in tissue engineering have witnessed luffa-derived scaffolds, exhibiting their exceptional potential in cellular proliferation, biocompatibility, appropriate interconnectivity, and biomechanical strength. studies involved implanting fabricated scaffolds subcutaneously in Wistar rats to evaluate their impact on the heart, liver, and kidneys. This approach provided a safe and minimally invasive means to evaluate scaffold compatibility with surrounding tissues. Male Wistar rats were categorized into four distinct groups, Group A, B, C, and D are referred to as 3% LC implanted scaffolds, 5% LC implanted scaffolds, control (without luffa scaffolds), and Sham (without any scaffold implantation), respectively. Histological analysis in all the groups indicated that the animal models did not exhibit any signs of inflammation or toxicity, suggesting favorable tissue response to the implanted scaffolds. Initial observations revealed elevated levels of enzymes and biomarkers in the experimental groups after a 24 h interval, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin, creatine kinase-MB (CK-MB), and serum creatinine. However, these parameters normalized 3 weeks post-implantation, with no significant increase compared to the control groups, suggesting that the implanted luffa-based scaffolds did not induce adverse effects on the heart, liver, and kidneys. Furthermore, the scaffold's significant pore size and porosity enable it to release drugs, including antibacterial medications. This study demonstrates promising results, indicating excellent scaffold porosity, sustained drug release, affirming the biocompatibility, absence of inflammatory responses, and overall tissue compatibility highlighting the immense potential of these luffa-based scaffolds in various tissue engineering and regenerative medicine applications.
最近的组织工程进展见证了丝瓜衍生支架的出现，它们在细胞增殖、生物相容性、适当的连通性和生物力学强度方面表现出了非凡的潜力。研究涉及将制备好的支架皮下植入 Wistar 大鼠体内，以评估它们对心脏、肝脏和肾脏的影响。这种方法提供了一种安全且微创的方法来评估支架与周围组织的相容性。雄性 Wistar 大鼠被分为四个不同的组，A 组、B 组、C 组和 D 组分别被称为植入 3%LC 支架、植入 5%LC 支架、对照组（无丝瓜支架）和假手术组（无任何支架植入）。所有组别的组织学分析表明，动物模型没有表现出任何炎症或毒性迹象，这表明植入的支架对组织有良好的反应。最初的观察结果显示，实验组在 24 小时后，包括天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT）、碱性磷酸酶（ALP）、胆红素、肌酸激酶同工酶-MB（CK-MB）和血清肌酐在内的酶和生物标志物水平升高。然而，这些参数在植入后 3 周内恢复正常，与对照组相比没有显著增加，这表明植入的丝瓜基支架不会对心脏、肝脏和肾脏产生不良影响。此外，支架的显著孔径和孔隙率使其能够释放药物，包括抗菌药物。这项研究显示出了有前景的结果，表明支架具有极好的孔隙率和持续的药物释放，证实了其生物相容性、无炎症反应以及整体组织相容性，突出了这些丝瓜基支架在各种组织工程和再生医学应用中的巨大潜力。
